GlobeNewswire Inc | Sep 2, 2021 04:01PM EDT

September 02, 2021

BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19th Annual Global Healthcare Conference taking place virtually September 9-15, 2021. Details for the live presentation can be found below.

Presentation Format: Fireside chatDate: Thursday, September 9, 2021Time: 5:00 PM ET

AboutLarimar Therapeutics

Larimar Therapeutics, Inc.(Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimars lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in theU.S.as a potential treatment for Friedreich's ataxia.Larimaralso plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com(212) 915-2569

Company Contact:Michael CelanoChief Financial Officermcelano@larimartx.com(484) 414-2715